TrialsgrambetaRCTs are beautiful

POST

2006

Prevention of Syncope Trial

In 208 patients with recurrent vasovagal syncope and a positive tilt test, metoprolol at the highest tolerated dose did not reduce the first recurrence of syncope over one year compared with placebo.

Result

Efficacy: Time to first recurrence of syncope over 1 yearHR 0.89 (95% CI 0.63-1.25) · P = 0.49

Below 1 favours metoprolol at the highest tolerated dose, above 1 favours placebo.

Also reported: 75 of 208 patients had at least one recurrence; Neither age nor the need for isoproterenol during tilt testing predicted benefit.

Original publication
Subtopic
Vasovagal syncope
Design
Double-blind, placebo-controlled RCT
Relevance
Important: one of several pillars.
Source
Sheldon R, Connolly S, Rose S, et al. Circulation. 2006;113(9):1164-1170.doi 10.1161/CIRCULATIONAHA.105.535161

Discussion & critique

The first properly designed placebo-controlled trial of a beta-blocker in vasovagal syncope, neutral despite a highly symptomatic cohort; its modest size still leaves room for a small effect. It is the reason beta-blockers are not recommended for reflex syncope.